Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 1;31(2):78-83.
doi: 10.1097/MED.0000000000000846. Epub 2023 Nov 23.

Multifactorial chylomicronemia syndrome

Alan Chait  1
Affiliations
Review

Multifactorial chylomicronemia syndrome

Alan Chait. Curr Opin Endocrinol Diabetes Obes. .

Abstract

Purpose of review: The aim of this review was to understand the role of multifactorial chylomicronemia syndrome (MFCS) as a cause of severe hypertriglyceridemia; to distinguish it from other causes of severe hypertriglyceridemia; and to provide a rational approach to treatment.

Recent findings: There have been advances in understanding the genetic underpinning of MFCS, and a better appreciation as to how to differentiate it from the much rarer familial chylomicronemia syndrome, in which there are substantial differences in the approach to their treatment. New approaches to triglyceride lowering will help reduce the risk of pancreatitis, the major complication of MFCS.

Summary: MCSF is a condition in which plasma triglyceride levels are severely elevated, usually to due exacerbation of common genetic forms of hypertriglyceridemia by secondary causes of hypertriglyceridemia and/or triglyceride-raising drugs. Triglyceride-induced pancreatitis can be prevented by markedly reducing triglyceride levels by treating secondary causes and/or eliminating of triglyceride-raising drugs, and by using triglyceride-lowering drugs, especially fibrates. MFCS also increases cardiovascular disease risk, for which lifestyle measures and drugs are required.

PubMed Disclaimer

References

    1. Dron JS, Hegele RA. Genetics of hypertriglyceridemia. Front Endocrinol 2020; 11:455.
    1. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2:655–666.
    1. Goldberg RB, Chait A. A comprehensive update on the chylomicronemia syndrome. Front Endocrinol 2020; 11:593931.
    1. Chen YQ, Pottanat TG, Zhen EY, et al. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. J Lipid Res 2021; 62:100068.
    1. Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL. Evidence for a common saturable triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 1973; 52:1578–1585.

MeSH terms